Omeprazole

Proton pump inhibitors

ATC code: A02BC01 (Omeprazole)

Brand names

Prilosec, Zegerid

Mechanism of action

Irreversibly inhibits the H+/K+-ATPase in gastric parietal cells — the final step of gastric acid secretion. Converted to its active form in the acidic environment of parietal cell canaliculi, where it binds the enzyme covalently. The effect persists until new H+/K+-ATPase molecules are synthesized (about 24 hours).

Indications

Gastroesophageal reflux disease

First line

PPIs are first-line for GERD in adults per 2022 and CG184. Standard dose: omeprazole 20 mg once daily for 4–8 weeks in non-erosive disease, 40 mg in erosive disease. If the response is inadequate, assess adherence, timing, functional heartburn, and alternative diagnoses. Long-term maintenance uses the lowest effective dose.

Sources

Helicobacter pylori infection

First line

A component of H. pylori eradication regimens per Maastricht VI/Florence Consensus 2022. In triple therapy: omeprazole 20 mg BID with amoxicillin and clarithromycin. In bismuth quadruple therapy: with tetracycline and metronidazole. Course duration 14 days. PPI is continued at least 4 more weeks after antibiotics for mucosal healing.

Sources

NSAID gastropathy prophylaxis

First line

Gastroprotection is indicated in long-term NSAID users with risk factors: age over 65, prior peptic ulcer or GI bleeding, concomitant anticoagulants, antiplatelet drugs, or glucocorticoids, and high NSAID doses. Routine gastroprotection in low-risk patients is not recommended.

Sources

Peptic ulcer disease

First line

Standard therapy for peptic ulcer disease: omeprazole 20–40 mg once or twice daily for 4–8 weeks depending on ulcer location. In H. pylori-positive patients, as part of an eradication regimen. Maintenance therapy is used in recurrent ulcers, H. pylori-negative ulcers, and chronic NSAID users.

Sources

Marketing claims without evidence base

The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.

PPI for NSAID gastric prophylaxis in low-risk patients

Not recommended

Omeprazole is widely prescribed as gastric protection for short NSAID courses in patients without GI-bleed risk factors, and for general post-meal discomfort. 2022 and 2022 recommend PPI plus NSAID only with risk factors: age over 60, ulcer history, anticoagulants, antiplatelets, high-dose NSAIDs. The Targownik 2010 BMJ analysis and subsequent systematic reviews show long-term PPI signals: B12 deficiency, hypomagnesemia, fractures ( Drug Safety Communications 2010, 2011) and Clostridioides difficile infection (FDA DSC 2012).

Sources

Practical notes

Timing and administration

Take 30–60 minutes before the first meal. This is a fundamental rule: PPIs only bind active H+/K+-ATPase molecules, and the enzyme activates with the first food intake. Taking it after a meal or on an empty stomach without food markedly reduces efficacy. Swallow the capsule whole (the enteric coating protects the drug from acid inactivation).

Monitoring

On long-term therapy (over 1 year), check serum magnesium yearly, especially in patients on diuretics or digoxin. Check vitamin B12 in patients over 60 on long-term PPI therapy. Assess bone mineral density in postmenopausal women after 5 years of therapy. Long-term therapy requires periodic re-evaluation of indications.

Special situations

After long-term use (over 3 months) and abrupt discontinuation, rebound hyperacidity can occur — heartburn symptoms return from transient hyperacidity. Gradual taper is preferred with transition to the lowest effective dose, every other day, then H2 blockers as needed. Co-administration with clopidogrel: omeprazole and esomeprazole inhibit CYP2C19 more strongly than other PPIs in vitro, which underlies the historical 2009 caution. The clinical relevance, however, has been refuted by the COGENT RCT (Bhatt DL et al. NEJM 2010) and subsequent studies: no difference in cardiovascular outcomes was seen between DAPT patients receiving omeprazole and those who did not. Current position: PPIs are indicated during dual antiplatelet therapy to reduce GI bleeding risk; choice of molecule is not critical.

Common myths

Myth: 'PPIs are harmless and can be taken for years without monitoring'. Fact: long-term use is associated with hypomagnesemia, vitamin B12 deficiency, increased fracture risk, acute interstitial nephritis, C. difficile infection, and community-acquired pneumonia. Prescribing should be justified and periodically reviewed.

Myth: 'heartburn requires lifelong treatment'. Fact: many patients do well with lifestyle changes (weight, meals, sleep position) and a short PPI course. Lifelong therapy is justified in severe erosive esophagitis, Barrett esophagus, or Zollinger-Ellison syndrome.

Drug–drug interactions

12 pairs found. Sorted from critical to minor.

Critical

Atazanavir

Antiretroviral, HIV protease inhibitor

Mechanism

Omeprazole raises gastric pH – atazanavir solubility drops, bioavailability falls 75%. ART fails with resistance risk.

Symptoms

Rising HIV viral load on apparently ongoing therapy.

Management

Combination contraindicated. Switch omeprazole to ranitidine (H2 blocker) given 12 hours apart from atazanavir.

Sources

Mechanism of action

Indications

Practical notes

Timing and administration

Monitoring

Special situations

Common myths

Drug–drug interactions

Check interaction with another drug

Official sources

Safety

Contraindications

Serious adverse effects

Common adverse effects

Uncommon adverse effects

PregnancyFDA C

Frequently asked

Mechanism of action

Indications

Practical notes

Timing and administration

Monitoring

Special situations

Common myths

Drug–drug interactions

Check interaction with another drug

Official sources

Safety

Contraindications

Serious adverse effects

Common adverse effects

Uncommon adverse effects

PregnancyFDA C

Frequently asked